Abstract: Fused pyridines of formula (I) and the pharmaceutically acceptable salts thereof have activity as inhibitors of c-Met and may thus be used to treat various diseases and disorders including cancer. Processes for synthesizing the compounds are also described.

Abstract: Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; R3 is H or C1-C6 alkyl; and R4 is an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Abstract: A method of and system to determine which channels are accessible by a communication device in a push-to-talk communication network are disclosed. The method may comprise sending an identifying network connectivity message to the communication device across a particular network channel, the identifying network connectivity message including an identification code. The method further comprises querying the communication device for the identification code to determine if the communication device successfully received the identifying network connectivity message, thereby to establish if the particular network channel is accessible by the communication device.

Abstract: Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Abstract: The invention provides the compounds of formula (I) and pharmaceutically acceptable salts thereof, in which: R1 and R2 are independently selected from the group consisting of H, C1-6alkyl, C1-2alkyl substituted by one to five fluorine atoms, C3-6alkenyl, C3-6alkynyl, C3-10cycloalkylC0-6alkyl, C4-12bridged cycloalkyl, A(CR7R8)n and B(CR7R8)n; R3 is selected from the group consisting of C1-6alkyl, NH2 and R10CONH; R4 is C1-2alkyl substituted by one to five fluorine atoms; R5 is selected from the group consisting of H, C1-4alkyl, C1-2alkyl substituted with one to five fluorine atoms, halogen and C3-10cycloalkylC0-6alkyl, with the proviso that when R6 is H R5 is not H.

Abstract: A flow control device for dispensing a multi-phase oral composition. The device includes a housing, a restrictor and an insert that fits within and cooperates with the housing and restrictor to dispense the oral composition. A flowpath is formed in and around the insert, as well as in the housing such that the composition passes through one or more channels defined by the cooperative arrangement of the insert and housing. Changes in relative position between the insert and the housing facilitate selective alignment of the various channels with a discharge orifice formed in the housing such that a user can vary the way the proportions of discreet fluids making up the oral composition are dispensed through said orifice.

Abstract: The invention provides a pyrimidine compound of formula (I): wherein R1 and R2 have any of the values defined herein; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Abstract: The invention provides a pyrimidine compound of formula (I): wherein R1 and R2 have any of the values defined herein; or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Abstract: Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; R is H or C1-C6 alkyl; and R is an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Abstract: An electrochemical cell is provided that includes a housing that is polygonal in cross-section having a plurality of peripherally spaced corners. The electrochemical cell also includes an ion-conducting separator disposed in the housing. The ion-conducting separator has an anode surface defining a portion of an anode compartment and a cathode surface defining a portion of a cathode compartment. The electrochemical cell also includes an anode current collector system comprising at least one biasing component. The biasing component has a span section, a bias section and an interface section. The bias section is in wicking contact with the anode surface of the separator. The number of biasing components in the anode current collector system differs from the number of the peripherally spaced corners. An energy storage device including a plurality of the electrochemical cells in thermal and/or in electrical communication with each other. A method for forming the biasing component is provided.

Abstract: The invention provides a pyrimidine compound of formula (I): wherein R1, R2, and Y have any of the values defined herein; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Abstract: Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Abstract: A structural building component for a residential or light commercial building includes a PV laminate and a plastic frame disposed at least around the PV laminate. The plastic frame includes a first electrical connector for communication with the PV laminate and receptive to electrical connection with a contiguous PV laminate. The first electrical connector is configured to facilitate electrical and mechanical connection with the contiguous PV laminate and the frame includes a means for facilitating attachment to the building structure.

Abstract: Technologies are described herein for customizing media routing for a conference. In one method, a request to modify a routing table is received. The routing table specifies connections between a plurality of sources and a plurality of sinks. The method determines whether the request to modify the routing table is permitted. Upon determining that the request to modify the routing table is permitted, the routing table is modified according to the request.

Abstract: An motorized stain-removal brush is provided. A method of using motorized stain-removal brush for cleaning inanimate surfaces is also provided. The motorized stain-removal brush includes a handle having a motor disposed therein, a head having a longitudinal axis, and a neck disposed between the handle and the head. Bristle holders are associated with the head. The motor is operatively connected to the bristle holder.

Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.